BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

925 related articles for article (PubMed ID: 24210875)

  • 1. Nanoparticle-directed sub-cellular localization of doxorubicin and the sensitization breast cancer cells by circumventing GST-mediated drug resistance.
    Zeng X; Morgenstern R; Nyström AM
    Biomaterials; 2014 Jan; 35(4):1227-39. PubMed ID: 24210875
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of new potential anticancer drugs designed to overcome glutathione transferase mediated resistance.
    Johansson K; Ito M; Schophuizen CM; Mathew Thengumtharayil S; Heuser VD; Zhang J; Shimoji M; Vahter M; Ang WH; Dyson PJ; Shibata A; Shuto S; Ito Y; Abe H; Morgenstern R
    Mol Pharm; 2011 Oct; 8(5):1698-708. PubMed ID: 21851097
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A mechanistic study of enhanced doxorubicin uptake and retention in multidrug resistant breast cancer cells using a polymer-lipid hybrid nanoparticle system.
    Wong HL; Bendayan R; Rauth AM; Xue HY; Babakhanian K; Wu XY
    J Pharmacol Exp Ther; 2006 Jun; 317(3):1372-81. PubMed ID: 16547167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. pH-Dependent doxorubicin release from terpolymer of starch, polymethacrylic acid and polysorbate 80 nanoparticles for overcoming multi-drug resistance in human breast cancer cells.
    Shalviri A; Raval G; Prasad P; Chan C; Liu Q; Heerklotz H; Rauth AM; Wu XY
    Eur J Pharm Biopharm; 2012 Nov; 82(3):587-97. PubMed ID: 22995704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multifunctional aptamer-based nanoparticles for targeted drug delivery to circumvent cancer resistance.
    Liu J; Wei T; Zhao J; Huang Y; Deng H; Kumar A; Wang C; Liang Z; Ma X; Liang XJ
    Biomaterials; 2016 Jun; 91():44-56. PubMed ID: 26994877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reversibly crosslinked hyaluronic acid nanoparticles for active targeting and intelligent delivery of doxorubicin to drug resistant CD44+ human breast tumor xenografts.
    Zhong Y; Zhang J; Cheng R; Deng C; Meng F; Xie F; Zhong Z
    J Control Release; 2015 May; 205():144-54. PubMed ID: 25596560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Redox-responsive nanoparticles from the single disulfide bond-bridged block copolymer as drug carriers for overcoming multidrug resistance in cancer cells.
    Wang YC; Wang F; Sun TM; Wang J
    Bioconjug Chem; 2011 Oct; 22(10):1939-45. PubMed ID: 21866903
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficient induction of apoptosis by doxorubicin coupled to cell-penetrating peptides compared to unconjugated doxorubicin in the human breast cancer cell line MDA-MB 231.
    Aroui S; Brahim S; De Waard M; Bréard J; Kenani A
    Cancer Lett; 2009 Nov; 285(1):28-38. PubMed ID: 19523755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer.
    Wong HL; Bendayan R; Rauth AM; Wu XY
    J Control Release; 2006 Dec; 116(3):275-84. PubMed ID: 17097178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DOX-loaded peptide dendritic copolymer nanoparticles for combating multidrug resistance by regulating the lysosomal pathway of apoptosis in breast cancer cells.
    Wang J; Li N; Cao L; Gao C; Zhang Y; Shuai Q; Xie J; Luo K; Yang J; Gu Z
    J Mater Chem B; 2020 Feb; 8(6):1157-1170. PubMed ID: 31951231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-molecular-weight protamine-modified PLGA nanoparticles for overcoming drug-resistant breast cancer.
    Wang H; Zhao Y; Wang H; Gong J; He H; Shin MC; Yang VC; Huang Y
    J Control Release; 2014 Oct; 192():47-56. PubMed ID: 25003794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Co-delivery of thioridazine and doxorubicin using polymeric micelles for targeting both cancer cells and cancer stem cells.
    Ke XY; Lin Ng VW; Gao SJ; Tong YW; Hedrick JL; Yang YY
    Biomaterials; 2014 Jan; 35(3):1096-108. PubMed ID: 24183698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pegylated phosphotidylethanolamine inhibiting P-glycoprotein expression and enhancing retention of doxorubicin in MCF7/ADR cells.
    Wang J; Qu H; Jin L; Zeng W; Qin L; Zhang F; Wei X; Lu W; Zhang C; Liang W
    J Pharm Sci; 2011 Jun; 100(6):2267-77. PubMed ID: 21246559
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Folate-mediated mitochondrial targeting with doxorubicin-polyrotaxane nanoparticles overcomes multidrug resistance.
    Wang H; Yin H; Yan F; Sun M; Du L; Peng W; Li Q; Feng Y; Zhou Y
    Oncotarget; 2015 Feb; 6(5):2827-42. PubMed ID: 25605018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The tumor accumulation and therapeutic efficacy of doxorubicin carried in calcium phosphate-reinforced polymer nanoparticles.
    Min KH; Lee HJ; Kim K; Kwon IC; Jeong SY; Lee SC
    Biomaterials; 2012 Aug; 33(23):5788-97. PubMed ID: 22591612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel doxorubicin-mitomycin C co-encapsulated nanoparticle formulation exhibits anti-cancer synergy in multidrug resistant human breast cancer cells.
    Shuhendler AJ; Cheung RY; Manias J; Connor A; Rauth AM; Wu XY
    Breast Cancer Res Treat; 2010 Jan; 119(2):255-69. PubMed ID: 19221875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Doxorubicin and curcumin co-delivery by lipid nanoparticles for enhanced treatment of diethylnitrosamine-induced hepatocellular carcinoma in mice.
    Zhao X; Chen Q; Li Y; Tang H; Liu W; Yang X
    Eur J Pharm Biopharm; 2015 Jun; 93():27-36. PubMed ID: 25770771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanoparticle-mediated combination chemotherapy and photodynamic therapy overcomes tumor drug resistance in vitro.
    Khdair A; Handa H; Mao G; Panyam J
    Eur J Pharm Biopharm; 2009 Feb; 71(2):214-22. PubMed ID: 18796331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enzyme and Thermal Dual Responsive Amphiphilic Polymer Core-Shell Nanoparticle for Doxorubicin Delivery to Cancer Cells.
    Kashyap S; Singh N; Surnar B; Jayakannan M
    Biomacromolecules; 2016 Jan; 17(1):384-98. PubMed ID: 26652038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reversing of multidrug resistance breast cancer by co-delivery of P-gp siRNA and doxorubicin via folic acid-modified core-shell nanomicelles.
    Wu Y; Zhang Y; Zhang W; Sun C; Wu J; Tang J
    Colloids Surf B Biointerfaces; 2016 Feb; 138():60-9. PubMed ID: 26655793
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 47.